Pharma News

Bristol Myers Squibb’s Phase III Clinical Trial for Zeposia Fails to Meet Primary Endpoint of Clinical Remission in Crohn Disease

Company says it remains committed to advancing research for immune-mediated diseases and intends to share trial data at a later date.

Source link
#Bristol #Myers #Squibbs #Phase #III #Clinical #Trial #Zeposia #Fails #Meet #Primary #Endpoint #Clinical #Remission #Crohn #Disease

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *